Ratifi Español Sign in
Ratifi

Federal bills from Congress.gov. State bills from Open States.

SB 844Session 2026

What changed between versions

11 paragraphs changed+4 words added−24 removed

Highlighted text was added in the newer version. Struck-through text was removed.

Florida Senate

-

ENROLLED

2026

Legislature

CS for SB 844

By

the Appropriations Committee on Health and Human Services;

and Senator Jones

603-02826-26 2026844c1

1 A bill to be entitled

2026844er

1

2 An act relating to sickle cell disease care management

45 unchanged paragraphs

3 and treatment continuing education; amending s.

4 456.0301, F.S.; revising requirements for a continuing

5 education course on prescribing controlled substances

6 which health care practitioners are required to

7 complete; providing an effective date.

8

9 Be It Enacted by the Legislature of the State of Florida:

10

11 Section 1. Paragraph (a) of subsection (1) of section

12 456.0301, Florida Statutes, is amended to read:

13 456.0301 Requirement for instruction on controlled

14 substance prescribing.—

15 (1)(a) The appropriate board shall require each person

16 registered with the United States Drug Enforcement

17 Administration and authorized to prescribe controlled substances

18 pursuant to 21 U.S.C. s. 822 to complete a board-approved 2-hour

19 continuing education course on prescribing controlled substances

20 offered by a statewide professional association of physicians in

21 this state that is accredited to provide educational activities

22 designated for the American Medical Association Physician’s

23 Recognition Award Category 1 Credit or the American Osteopathic

24 Category 1-A continuing medical education credit as part of

25 biennial license renewal. The course must include information on

26 the current standards for prescribing controlled substances,

27 particularly opiates; alternatives to these standards;

28 nonpharmacological therapies; prescribing emergency opioid

29 antagonists;

and

the risks of opioid addiction following all

30 stages of treatment in the management of acute pain

; and the

31

treatment of pain for patients with sickle cell disease

. The

32 course may be offered in a distance learning format and must be

33 included within the number of continuing education hours

34 required by law. The department may not renew the license of any

35 prescriber registered with the United States Drug Enforcement

36 Administration to prescribe controlled substances who has failed

37 to complete the course. The course must be completed by January

38 31, 2019, and at each subsequent renewal. This paragraph does

39 not apply to a licensee who is required by his or her applicable

40 practice act to complete a minimum of 2 hours of continuing

41 education on the safe and effective prescribing of controlled

42 substances.

43 Section 2. This act shall take effect July 1, 2026.

Back to the full text